James Chu, MD
Endocrinology, Diabetes & Metabolism · Monterey, CANPI 1710969266
Payments from drug & device makers
Across 1,822 payments — averaging $615.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$497K
- Eli Lilly$265K
- Novo Nordisk AS$218K
- Boehringer Ingelheim$82K
- Sanofi-aventis U.S. LLC$33K
- AstraZeneca$21K
- plus $5K from 32 others
Across 4 payments — averaging $1507.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6K
What the payments were for
- Consulting fees$4,0001%
- Speaking & faculty fees$568,78589%
- Travel & lodging$43,4917%
- Food & beverage$22,6644%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 913 | $497,050 |
| Eli Lilly | 31 | $264,562 |
| Novo Nordisk AS | 363 | $217,795 |
| Boehringer Ingelheim | 143 | $82,358 |
| Sanofi-aventis U.S. LLC | 72 | $32,788 |
| AstraZeneca(2 entities) | 68 | $21,441 |
| Abbott | 43 | $828 |
| Amgen(2 entities) | 28 | $615 |
| Bayer | 11 | $410 |
| Dexcom, Inc. | 13 | $375 |
| Xeris Pharmaceuticals, Inc. | 18 | $364 |
| Mannkind Corporation | 17 | $329 |
| Radius Health, Inc. | 13 | $319 |
| AbbVie | 16 | $262 |
| Novo Nordisk | 6 | $234 |
| Corcept Therapeutics | 6 | $179 |
| Johnson & Johnson | 10 | $157 |
| Merck | 7 | $123 |
| Kyowa Kirin, Inc. | 5 | $115 |
| Medtronic(2 entities) | 4 | $107 |
| Ascendis Pharma Endocrinology Inc | 4 | $103 |
| Madrigal Pharmaceuticals | 3 | $100 |
| BETA Bionics, Inc. | 3 | $72 |
| Ascensia Diabetes Care US Inc. | 3 | $69 |
| Cequr Corporation | 1 | $63 |
| Shire North American Group Inc | 3 | $61 |
| Insulet Corporation | 3 | $59 |
| Tandem Diabetes Care, Inc. | 2 | $58 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $43 |
| Boston Scientific | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Soleno Therapeutics, Inc. | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$231,543
- MOUNJARO$160,621
- JARDIANCE$142,700
- SOLIQUA 100/33$23,377
- FARXIGA$20,270
- TOUJEO$8,363
- Kerendia$234
- FREESTYLE LIBRE 3$113
How this compares
$1,121,250 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 326 | $356,548 |
| TrulicityDulaglutide | 192 | $344,021 |
| JardianceEmpagliflozin | 105 | $131,390 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 80 | $105,470 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 70 | $89,319 |
| OzempicSemaglutide | 60 | $65,641 |
| TradjentaLinagliptin | 50 | $63,766 |
| JanuviaSitagliptin Phosphate | 41 | $55,447 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $40,197 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $36,411 |
| TymlosAbaloparatide | 13 | $35,884 |
| RybelsusSemaglutide | 18 | $27,852 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $26,752 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $23,283 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $17,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $497,050 | $700,569518 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $82,358 | $300,627235 claims |
| Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30 | $234 | $97,97489 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $32,788 | $89,31970 claims |
| MerckJanuvia, Janumet Xr | $123 | $82,19962 claims |
| Radius Health, Inc.Tymlos | $319 | $35,88413 claims |
| AbbVieSynthroid | $262 | $17,237221 claims |
| AstraZenecaFarxiga | $21,441 | $15,05711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Monterey
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.